VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Free Report) has been given a consensus recommendation of “Reduce” by the five analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $0.95.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Monday, August 31st.
Get Our Latest Analysis on VistaGen Therapeutics
VistaGen Therapeutics Price Performance
VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. As a group, sell-side analysts predict that VistaGen Therapeutics will post -1.45 EPS for the current fiscal year.
Institutional Investors Weigh In On VistaGen Therapeutics
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in VistaGen Therapeutics during the 2nd quarter valued at about $78,000. ADAR1 Capital Management LLC acquired a new position in shares of VistaGen Therapeutics in the 2nd quarter valued at about $79,000. Finally, Renaissance Technologies LLC increased its holdings in shares of VistaGen Therapeutics by 81.2% in the 1st quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock valued at $166,000 after purchasing an additional 130,509 shares during the period. 78.39% of the stock is currently owned by institutional investors and hedge funds.
VistaGen Therapeutics Company Profile
Vistagen Therapeutics, Inc (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines.
Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder.
Further Reading
- Five stocks we like better than VistaGen Therapeutics
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
